Related Experiment Video

Updated: Aug 5, 2026

Simple and Efficient Production and Purification of Mouse Myelin Oligodendrocyte Glycoprotein for Experimental Autoimmune Encephalomyelitis Studies
10:47

Simple and Efficient Production and Purification of Mouse Myelin Oligodendrocyte Glycoprotein for Experimental Autoimmune Encephalomyelitis Studies

Published on: October 27, 2016

Identification of T-cell epitopes of autoantigens using recombinant proteins; studies on experimental autoimmune

Y Zhang1, S Frutiger, G J Hughes

  • 1Neurology Service, Cantonal University Hospital, Lausanne.

Immunology
|December 1, 1990
PubMed

In the Lewis rat, T-cell lines from animals immunized with native or denatured Torpedo nAChR recognize the Torpedo-derived recombinant protein T alpha X1 omega (alpha-2-200) but not the equivalent mouse- or chick-derived recombinant proteins X4 omega or C alpha X1 omega (alpha 6-216 and alpha 35-216, respectively). T-cell lines derived from animals immunized with T alpha X1 omega, X4 omega or C alpha X1 omega are specific for the homologous protein. This lack of cross-species reactivity suggests caution in the use of Torpedo nAChR-selected lines generated from human patients. Proteolysis and fractionation of the products by reverse-phase HPLC was effective in localization of a T-cell epitope of X4 omega, a mouse-derived recombinant protein. With Lewis rats, the major epitope of T alpha X1 omega is alpha 97-112. However, the major epitope of the mouse-derived protein, X4 omega, as determined by proteolytic digestion and fractionation of the products by reverse-phase HPLC, is alpha 14-22. This shift in T-cell epitope between closely related proteins may result from the conservation of sequence of alpha 97-112 between mammalian species.

More Related Videos

Antigenic Liposomes for Generation of Disease-specific Antibodies10:31

Antigenic Liposomes for Generation of Disease-specific Antibodies

Published on: October 25, 2018

Quantification of Autoreactive Antibodies in Mice upon Experimental Autoimmune Encephalomyelitis05:55

Quantification of Autoreactive Antibodies in Mice upon Experimental Autoimmune Encephalomyelitis

Published on: December 1, 2023

Related Concept Videos

Hybridoma Technology01:31

Hybridoma Technology

Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation, polyethylene glycol...
Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
Myasthenia Gravis: Diagnostic Tests01:15

Myasthenia Gravis: Diagnostic Tests

Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
Myasthenia Gravis ll: Pathophysiology01:22

Myasthenia Gravis ll: Pathophysiology

The disease process of myasthenia gravis begins at the neuromuscular junction, where antibodies attack key proteins needed for muscle activation. This immune reaction weakens signal transmission, leading to the characteristic muscle fatigue and weakness that define the condition.Immune-Mediated DamageIn most individuals, antibodies target acetylcholine receptors (AChRs) on the postsynaptic membrane of muscle cells. By blocking acetylcholine binding, these antibodies prevent the nerve signal...